Volume 3, Issue 10, 2025

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

UNRAVELING CYSTIC FIBROSIS: CURRENT PERSPECTIVES ON IMPLICATIONS FOR DIAGNOSIS AND THERAPEUTIC STRATEGIES

Shahid Mahmood[*1], Areeba Saif Ullah[2], Syeda Nigha Zainab[3], Sehar Ijaz[4], Kinza[5], Orwa Imtiaz[6]

[*1,2,3,4,5,6]*Department of Zoology, University of Gujrat, Gujrat 50700, Pakistan*

[*1]shahid.mahmood@uog.edu.pk

DOI: https://doi.org/10.5281/zenodo.18168774

Keywords

Cystic Fibrosis, Regulator Gene, Mutations, Ivacaftor, Lumacaftor, Tezacaftor

Article History

Received: 20 October 2025

Accepted: 15 December 2025

Published: 31 December 2025

Copyright @Author

Corresponding Author: *

Shahid Mahmood

Abstract

Cystic Fibrosis is a serious and complex sickness that influences various organs, but its most serious impact is seen in the breathing gadget, where continuous infection, recurrent infections and airway clogging gradually ruin respiratory feature. By and large patients are recognized at a young age almost over three quarters before the age of. And many now continue to exist well into adulthood. The disease is linked to more than 2,000 one of a kind versions inside the Cystic Fibrosis Transmembrane Conductance Regulator gene and is the reason the huge diversity in signs and therapy impact among patients present day remedy in large part revolves round Cystic Fibrosis Transmembrane Conductance Regulator-concentrated on pills along with ivacaftor, lumacaftor and tezacaftor. Those tablets are designed to beautify the feature of the defective Cystic Fibrosis Transmembrane Conductance Regulator protein and feature drastically progressed pulmonary function for plenty individuals regardless of their healing gain, those treatments maintain to face widespread drawbacks. Best a constrained subset of Cystic Fibrosis Transmembrane Conductance Regulator mutations indicates a robust therapeutic final results to presently available modulators. Further, the financial pressure of those tablets is noticeably steeply-priced and there are ongoing apprehensions regarding their extended protection and lasting efficacy. Disorder control is hindered by using the restrained effectiveness of existing genetic remedies and demanding situations associated with patient adherence. This have a look at objectives to assess the therapeutic overall performance of Cystic Fibrosis Transmembrane Conductance Regulator modulators throughout special patient classes, severely analyze contemporary remedy processes and examine how variations in Cystic Fibrosis Transmembrane Conductance Regulator genotypes and phenotypic expression impact therapeutic consequences. Furthermore, it draws interest to cutting-edge clinical trials and rising future possibilities, which include personalized healing treatments and advanced DNA amendment techniques. Those emerging techniques maintain potential for broader mutation range, achieving greater lengthy-lasting healing blessings and ultimately beautify regulation of Cystic Fibrosis progression.

INTRODUCTION

Cystic Fibrosis is a genetic disease caused by alternations in the Cystic Fibrosis Transmembrane Conductance Regulator gene. This gene normally helps control the movement of water and salt through the body's cell. When the Cystic Fibrosis Transmembrane Conductance Regulator protein is

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

absent or does not work properly, it leads to problems in more than one organs particularly the lungs and digestive system. More than 30,000 patients in the United States and nearly 89.000 globally are currently living with this condition. Because several body systems are impacted, cystic fibrosis can reduce overall physical conditions and shorten lifespan (Ong *et al.*, 2023).

Cystic Fibrosis Prognosis and Life Expectancy

It is an inherited disorder that affects various organs and body systems, including the airways, pancreas, colon, and reproductive system. The discovery of a rising number of Cystic Fibrosis Transmembrane Conductance Regulator gene patterns has led to a growth in the diagnosed Cystic Fibrosis population, which has consequently influenced overall statics related to expected course and health outcomes. As lifespan continues to extend, there is an increasing need to precisely predict disease outcomes and evaluate prognosis in individuals with Cystic Fibrosis (Donos *et al.*, 2025).

It is an autosomal recessive genetic disease caused by alternations in the Cystic Fibrosis Transmembrane Conductance Regulator gene. Typical or classical symptoms include persistent ling infections, impaired pancreatic function and elevated sweat chloride levels, although many patients may show subtle or unusual symptoms. The diagnosis of Cystic Fibrosis is mainly based on identifying genetic or functional impairments in the Cystic Fibrosis Transmembrane Conductance Regulator gene. Treatment usually involves pancreatic enzyme supplementation, drugs that thin or loosen mucus, chest physical therapy and antimicrobial treatment to reduce infections and enhance lungs function (Wdowiak *et al.*, 2024).

Cystic Fibrosis-Like Disorders

Cystic fibrosis like disorders are conditions that show comparable clinical features with cystic fibrosis but arise from distinct genetic causes, making them challenging and complex to diagnose. Recent research has recognized mutations in the AGR2 gene as a new cause of hereditary disorder similar to cystic fibrosis, known as RIFTD syndrome. Diagnostic assessments included sweat chloride testing, chest x-ray and DNA analysis to identify AGR2 mutations. Therapeutic outcomes and disease progression were observed over a one-year follow-up period (Salehzadeh *et al.*, 2025).

Cystic fibrosis affects around 89,000 patients worldwide and is linked to a spectrum of health problems related to impaired gland function, including long-term respiratory bacterial infections and decreased life expectancy. Primary treatments for lung complications typically include medications that thin or loosen mucus, inflammation-reducing drugs and antibacterial therapy to treat infection infections and decrease inflammation. Additionally, approximately 90% of people with cystic fibrosis aged two years or older may gain advantage from a combination therapy of ivacaftor, tezacaftor and elexacaftor which targets the fundamental genetic defect in the Cystic Fibrosis Transmembrane Conductance Regulator protein (Bonnie *et al.*, 2023).

Cystic Fibrosis: Molecular Genetics and Pathophysiology:

The positional cloning of the gene responsible for cystic fibrosis marked an essential first step in understanding the primary abnormality and pathophysiology of the disorder. This study provides a key developments of the landmark discoveries and contributing elements that led to the recognition of the Cystic Fibrosis Transmembrane Conductance Regulator gene. The updated structure of the Cystic Fibrosis Transmembrane Conductance Regulator gene, based on the entire sequence obtained from the human genome project, is presented, along with short summaries of transcriptional regulatory sequences, the function of mRNA splicing in control of gene expression and fibrosis disease, and associated genetic regions in the human genome and other comparative genomics (Dorfam *et al*, 2013).

Mutations in the gene responsible for the life-threatening disease cystic fibrosis cause defective passage of multiple electrolytes across various epithelial tissues. Within just three years after the Cystic Fibrosis Transmembrane Conductance Regulator gene was cloned, researchers developed the first cystic fibrosis mouse models. These cystic fibrosis mouse models have since provided in-depth insights into the functional consequences cystic fibrosis across multiple tissues or affected systems.

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

The heterogeneity in how the disease appears among mouse models is linked to the different gene-targeting approaches used to create the models, as well as the diverse murine genetic backgrounds (Grubb *et al.*, 1999).

Cystic Fibrosis Phenotype:

The effects of abnormal Cystic Fibrosis Transmembrane Conductance Regulator function often start even during fatal development.

In males, Cystic Fibrosis Transmembrane Conductance Regulator dysfunction can interfere with the prenatal development of the embryonic male genital ducts, resulting in congenital bilateral absence of the vas deferens, which leads to reproductive inability in almost all men with cystic fibrosis.

Females usually do not show anatomical defects but they may face reproductive challenges due to sticky cervical mucus. Prenatal ultrasonographic findings that indicate possible risk for cystic fibrosis include bright-appearing intestines on ultrasound with or without inflammation caused by leaked meconium, intestinal enlargement or an absent gallbladder.

Intestinal obstruction by thick meconium occurs in up to 20% of newborns affected cystic fibrosis and is stronger associated with the disease, with around 90% of such cases found in infants with cystic fibrosis (Schrijver *et al.*, 2015).

The impact of different Cystic Fibrosis Transmembrane Conductance Regulator alleles on clinical variation in cystic fibrosis is evaluated through genotype-phenotype correlation. These studies have shown that the strength of correlation between Cystic Fibrosis Transmembrane Conductance Regulator genotype and Cystic Fibrosis phenotype varies across organ systems, being strongest for digestive function and weakest for respiratory disease. The weak association between Cystic Fibrosis Transmembrane Conductance Regulator genotype and the severity of lung disease suggests that environmental factors and secondary genetic influences play a significant role. Overall, the phenotypic spectrum associated with Cystic Fibrosis Transmembrane Conductance mutations extends beyond the classical definition of cystic fibrosis (Zielenski 2000).

Clinical Manifestation of Cystic Fibrosis:

Cystic fibrosis is a genetic disorder that is caused by problems in the way chloride and other ions (like sodium and bicarbonates) are moved across cell membranes. This problem makes the body produce very thick and sticky fluids in many organs, including the lungs, pancreases, liver, intestine, and reproductive system and cause unusually salty sweat. These fluids can block passages, leading to ongoing lungs problems and infections (Yuelin *et al.*, 2021).

Beside lung problems, people with CF can also have digestive issues like distal intestinal obstruction, sugar disease, gallstones, and low salt in the body. Breathing problems may involve blocked passages, widened or destroyed airways, collapsed respiratory tracts or coughing up blood. These problems can make everyday activities harder, affect growth and nutrition, and may require ongoing medical care to manage symptoms and prevent serious disease (Subhanjan *et al.*, 2025).

Diagnosis and screening of cystic fibrosis:

Cystic fibrosis is usually treated when patients have common symptoms such as long lasting lung problems and poor nutrients absorption, a sweat chloride level above 60mmol/L and two disease-causing CFTR mutations. In milder cases, diagnosis can be difficult because symptoms may not very clear. Some people who show similar symptoms but have unclear test results are said to have CFTR-related disorder. Newborn screening helps find CF early, though some cases may still be unclear. Sweat chloride testing remains most reliable method, and identifying the exact CFTR mutation is significant for personalized treatment (Francois *et al.*, 2017).

Some CF cases remain unclear even after initial tests, which can cause stress for families and sometimes affect parent-child relationship. People born before universal newborn screening may have delayed or difficult diagnosis because CF symptoms can vary gently in age of onset and severity. These symptoms may include pancreas problems, breathing difficulties, long lasting sinus infections, or male infertility. Global data collection and lab advances have improved understanding of CF and related conditions like CRMS and CFSPID. The CF Foundation updated international guidelines to

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

standardize diagnosis and guide difficult case (White TB *et al.*, 2017).

In recent years, CF diagnosis evolved with widespread use of newborn screening. CF can now have recognized in many forms, from classic cases with poor pancreatic function to milder or single organ disease, as well as clear cases detected through screening. Diagnostic tools basically have improved, and updated criteria now cover newborn and parental screening, along with uncertain diagnoses in infant and adult showing CF-like symptoms (Rosenfeld *et al.*, 2016).

Structure and Function of CFTR in cystic fibrosis:

The CF gene is on human chromosome 7 and makes CFTR protein, which has a 1,480 amino acids. CFTR has complex structure: it starts with six sections that cross the cell membrane, followed by a part called NBD1 that bind ATP, another six membrane sections, and a second ATP binding part. A shorter form, TNR-CFTR, is found in kidney medulla of rats and humans (Morales, 1999).

The CFTR (cystic fibrosis transmembrane conductance regulator) is a special protein that act as a chloride channel, mainly found in apical membrane of epithelial cells, where it helps move salt and water across tissues. It has five main parts: two membrane-spanning domains that form the channel, two nucleotide-binding domains that control opening and closing using ATP, and a regulatory domain that switches the channel on or off through phosphorylation. Problems with CFTR lead to cystic fibrosis. Understanding its structure and knowing how each part functions helps to clarify its role in fluid balance, how its malfunction causes disease, and how it related to similar transport proteins (Sheppard *et al.*, 1999).

In addition to moving these ions, CFTR regulates the activity of other ion channels, including ENaC and CaCCs, coordinating overall ion and water transport in epithelial tissues. When CFTR is defective, it causes thick mucus, weak antimicrobial defense, abnormal fluid balance, and multi organ problems-the main feature of cystic fibrosis (Lukasiak, 2021).

Classification of CFTR mutations:

Cystic fibrosis (CF) is caused by mutations in the CFTR (ABCC7) gene, a severe inherited disease most common in Caucasians, affecting 1 in 2,500-4,500 newborns. The CFTR gene, located on chromosome 7, has 27 exons and produces a protein essential for normal cell function. Since its discovery in 1989, thousands of CFTR mutations have been identified and recorded in databases like CFTR1 and CFTR2, which classify mutations based on clinical impact and function. New treatments correct the defective CFTR protein based on patient's genotype. (Fanen *et al.*, 2014)

There are over 2000 CFTR gene variants, but around 360 actually cause cystic fibrosis. Basically CFTR mutations are grouped into six classes based on how they disrupt the protein:

Class I: No protein is made due to faulty mRNA.

Class II: Misfolded proteins are destroyed before reaching the cell surface (e.g., F508del).

Class III: Protein reach the membrane but don't open properly (gating defects, e.g., G551D).

Class IV: Proteins function poorly at the membrane causing milder symptoms (e.g., R117H).

Class V: Less protein is made due to splicing or promoter issues, usually mild.

Class VI: Proteins are unstable and quickly removed from the membrane.

Severe mutations (Classes I-III) cause typical CF with early lung and pancreatic problems, while milder mutations (Classes IV-VI) cause less severe or later symptoms. Knowing class helps tailor treatments to specific mutations (Anwar *et al.*, 2024).

Epidemiology and global prevalence of Cystic Fibrosis:

Cystic fibrosis is a condition that affects people all over the world, although the exact number of cases is not known. Over 100,000 people have CF, and this is rising due to longer life expectancy and better awareness. CF is no longer just a childhood disease-adult now make up over half of the population in countries with good care. Outcomes vary between countries, with high-income nations generally showing better survival. Early diagnosis and better treatments, including CFTR modulators, have improved quality of life and will likely increase the number of adults with CF (Burgle *et al.*, 2023).

Diagnosis of cystic fibrosis has seen major advances, especially with the introduction of triple combination therapies. Worldwide, approximately

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

162,000 patients live with CF, but only about 65% have been identified, and just 12% receive these modern treatments. Many cases go unidentified, particularly in developing nations, due to limited health care access and insufficient data collection. National CF registries provide useful data, but coverage differ and some patients are not included due to location or financial barriers. Improving these gaps could improve both diagnosis and access to successful therapies globally (Guo *et al.*, 2022).

Pulmonary Pathophysiology of Cystic Fibrosis:

At the cell level, the problem is that the CFTR protein fails to transport chloride and bicarbonate throughout the mobile membranes. This particular error reasons the liquid layer on the airways to dry out fast. Due to this, the tiny cilia hairs which may be imagined to easy out particles disintegrate and prevent working. Without this natural cleansing system, the mucus changes from a beneficial fluid into a thick and sticky sludge that adheres to the partitions and traps microorganism (Ratjen & Döring, 2003).

Over the years, this sticky mucus completely blocks the small air passages. This starts off evolved a horrific cycle of blockage and infection that is very difficult to forestall. The environment inside the lungs will become acidic and lacks oxygen that is right for risky bacteria to develop. Years of this damage permanently scar and widen the airways. This condition is known as bronchiectasis and it seriously limits how well the lungs can alternate gases (Button, et al., 2012).

Role of Chronic Infections and Inflammation in Cystic Fibrosis:

A primary hassle in cystic fibrosis is the steady bacterial contamination inside the lungs. Insects like Staphylococcus aureus and Pseudomonas aeruginosa settle in very early in a affected man or woman's life. Those microorganism are smart and survive by using building biofilms. you could think about biofilms as shielding shields that preserve the bacteria secure from antibiotics and the affected individual's very own immune machine. Due to those shields, infections can live for many years and are nearly now not possible to clean out (Chmiel & Davis, 2003).

The body attempts to combat those invaders by using sending a large amount of white blood cells referred to as neutrophils to the airways. Those cells launch strong enzymes to kill the microorganism, however In a CF lung, they often grow to be hurting healthy tissue instead. This ends in a country of normal infection that destroys the lungs in area of recuperation them. Finally, this drives the affected man or woman towards overall breathing failure (Elizur, et al., 2008).

Pancreatic Insufficiency and Digestive System Involvement in Cystic Fibrosis:

The damage isn't always clearly in the lungs because of the reality the same thick secretions moreover block the tubes inside the pancreas. This blockage stops critical digestive enzymes from undertaking the small intestine. This trouble frequently begins before the baby is even born. For the reason that enzymes are trapped within the pancreas, they begin to digest the organ itself. This technique is called autolysis and it turns wholesome tissue into vain fat and scars (Struyvenberg, et al., 2017).

Because the pancreas isn't operating right, sufferers struggle to absorb vitamins from their meals. They have got a hard time with fat and proteins mainly. This reasons signs and symptoms and signs like oily stools and horrific bloating. To healing this, sufferers must take enzyme capsules with each meal. This is vital due to the fact maintaining a healthy weight allows the lungs combat off infection higher (Ooi & Durie, 2016).

Impact of Cystic Fibrosis on Growth and Development:

Children with cystic fibrosis have a difficult time growing at a normal rate. They face big troubles right now. First, they cannot absorb nutrients properly, secondly their bodies' burn power too rapid. The bodily work of respiration thru blocked airways burns a selection of calories. Additionally, the regular inflammation hurries up their metabolism. In the occasion that they do not eat a very particular excessive-calorie diet regime, they'll now not benefit weight or pinnacle (Culhane, et al., 2016).

Those nutritional gaps do more than in reality keep a child small. They may put off puberty and make bones vulnerable. This gadget the extent for fractures

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

later in life. Studies indicates an instantaneous link between awful boom in early life and horrific lung health in adulthood. This is why medical doctors watch boom charts so cautiously. They regularly prescribe unique diets or maybe tube feeding to make certain the ones children broaden properly (Scaparrotta, et al., 2023).

Complications Associated with Cystic Fibrosis:

Patients are dwelling longer now due to higher remedy, but this brings new issues outdoor the lungs. The maximum common one is Cystic Fibrosis-related Diabetes or CFRD. This is particular from regular diabetes because it takes vicinity because of scarring at the pancreas. This scarring kills the cells that make insulin. If this sugar trouble isn't controlled, it speeds up lung damage and makes infections a whole lot worse (Moran, et al., 2010).

Patients moreover face dangers like liver disease wherein bile ducts get blocked. This leads to cirrhosis. Each different problem is osteoporosis or thinning of bones. In overdue degrees of the ailment, scary emergencies can manifest. Those embody a collapsed lung referred to as a pneumothorax or coughing up huge quantities of blood. The ones are lifestyles-threatening activities that want at once medical institution care (Elborn, et al., 2016).

Nutritional management in Cystic Fibrosis:

It is an inherited disorder that affects various organs and body systems, including the airways, pancreas, colon, and reproductive system. The discovery of a rising number of Cystic Fibrosis Transmembrane Conductance Regulator gene patterns has led to a growth in the diagnosed Cystic Fibrosis population, which has consequently influenced overall statics related to expected course and health outcomes. As lifespan continues to extend, there is an increasing need to precisely predict disease outcomes and evaluate prognosis in individuals with Cystic Fibrosis (Madalina Andreea Donos *et al.*, 2025).

It is an autosomal recessive genetic disease caused by alternations in the Cystic Fibrosis Transmembrane Conductance Regulator gene. Typical or classical symptoms include persistent ling infections, impaired pancreatic function and elevated sweat chloride levels, although many patients may show subtle or unusual symptoms. The diagnosis of Cystic Fibrosis is mainly based on identifying genetic or functional impairments in the Cystic Fibrosis Transmembrane Conductance Regulator gene. Treatment usually involves pancreatic enzyme supplementation, drugs that thin or loosen mucus, chest physical therapy and antimicrobial treatment to reduce infections and enhance lungs function (Natalia Wdowiak *et al.*, 2024).

Mutations in the gene responsible for the life-threatening disease cystic fibrosis cause defective passage of multiple electrolytes across various epithelial tissues. Within just three years after the Cystic Fibrosis Transmembrane Conductance Regulator gene was cloned, researchers developed the first cystic fibrosis mouse models. These cystic fibrosis mouse models have since provided in-depth insights into the functional consequences cystic fibrosis across multiple tissues or affected systems. The heterogeneity in how the disease appears among mouse models is linked to the different gene-targeting approaches used to create the models, as well as the diverse murine genetic backgrounds (Grubb, Richard C. Boucher *et al.*, 1999).

Liver and biliary complications in cystic Fibrosis:

Cystic fibrosis is a genetic disorder that is caused by problems in the way chloride and other ions (like sodium and bicarbonates) are moved across cell membranes. This problem makes the body produce very thick and sticky fluids in many organs, including the lungs, pancreases, liver, intestine, and reproductive system and cause unusually salty sweat. These fluids can block passages, leading to ongoing lungs problems and infections (Qionghua, yuelin *et al.*, 2021).

Beside lung problems, people with CF can also have digestive issues like distal intestinal obstruction, sugar disease, gallstones, and low salt in the body. Breathing problems may include blocked passages, widened or damaged airways, collapsed lungs, or coughing up blood. These complications can make everyday activities harder, affect growth and nutrition, and may require ongoing medical care to manage symptoms and prevent serious illness (Raj, Subhanjan *et al.*, 2025).

Females usually do not show anatomical defects but they may face reproductive challenges due to sticky cervical mucus. Prenatal ultrasonographic findings

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

that indicate possible risk for cystic fibrosis include bright-appearing intestines on ultrasound with or without inflammation caused by leaked meconium, intestinal enlargement or an absent gallbladder. Intestinal obstruction by thick meconium occurs in up to 20% of newborns affected cystic fibrosis and is stronger associated with the disease, with around 90% of such cases found in infants with cystic fibrosis (Iris Schrijver *et al.*, 2015).

Endocrine System Involvement in Cystic Fibrosis:

Some CF cases remain unclear even after initial tests, which can cause stress for families and sometimes affect parent-child relationship. People born before universal newborn screening may have delayed or difficult diagnosis because CF symptoms can vary gently in age of onset and severity. These symptoms may include pancreas problems, breathing difficulties, long lasting sinus infections, or male infertility. Global data collection and lab advances have improved understanding of CF and related conditions like CRMS and CFSPID. The CF Foundation updated international guidelines to standardize diagnosis and guide difficult case (White TB, *et al.*, 2017).

The CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) is a special protein that act as a chloride channel, mainly found in apical membrane of epithelial cells, where it helps move salt and water across tissues. It has five main parts: two membrane-spanning domains that form the channel, two nucleotide binding domains that control opening and closing using ATP, and a regulatory domain that switches the channel on or off through phosphorylation. Problems with CFTR lead to cystic fibrosis. Understanding its structure how each part works helps explain its role in fluid balance, how its malfunction causes disease, and how it relates to other similar transport proteins. (D N Sheppard, *et al.*, 1999)

Immune System Deregulation in Cystic Fibrosis:

Cystic fibrosis (CF) is caused by mutations in the CFTR (ABCC7) gene, a severe inherited disease most common in Caucasians, affecting 1 in 2,500-4,500 newborns. The CFTR gene, located on chromosome 7, has 27 exons and produces a protein essential for normal cell function. Since its discovery in 1989, thousands of CFTR mutations have been identified and recorded in databases like CFTR1 and CFTR2, which classify mutations based on clinical impact and function. New treatments correct the defective CFTR protein based on patient's genotype (Wohlhuter-Haddad, A., *et al.*, 2014).

CFTR helps transport important ions such as Cl^-, $HCO3^-$, and glutathione across cell membranes, which are essential for maintaining proper fluid balance, mucous hydration, and expansion, normal PH levels, and protection against infections. In addition to moving these ions, CFTR regulates the activity of other ion channels, including ENaC and CaCCs, coordinating overall ion and water transport in epithelial tissues. When CFTR is defective, it causes thick mucus, weak antimicrobial defense, abnormal fluid balance, and multi organ problems-the main feature of cystic fibrosis (Zajac, M. 2021).

Cardiovascular complications in cystic fibrosis:

Cystic fibrosis is an inherited autosomal recessive disorder that occur due to mutations in the cystic fibrosis Cross membrane conductor is regulator gene when the CFTR protein is absent or dysfunctional the apical surface of secretary epithelial cells in normal separation of chloride and bicarbonate Ions is distributed this defect is accompanied by increased sodium uptake and excessive mucus production which leads that dehydration and acidification of the airways surface liquid as a result clearance is compromised allowing recurrent respiratory infections and persistent inflammation that ultimately cause damage to the lung to date more than thousands CFTR gene mutations associated with cystic fibrosis has been reported (Prutha H., *et al.*, 2024).

Understanding the association between cystic fibrosis and cardiovascular disease may have significant clinical prevalent first healthcare provides should a recognize the elevated dress of cardiovascular complications in people with cystic fibrosis and incorporate routine cardiovascular evaluation into their care including regular blood pressure measurement and echocardiographic examination finding form this study indicate that individuals with cystic fibrosis exhibit a higher prevalence of hypertension which may be attributed to increased arterial stiffness and a greater systemic inflammation

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

load. But, it remains uncertain whether or not treatment with CFTR modulators right now contributes to elevate blood stress tiers (Helge, *et al.*, 2021).

The underlying mechanisms answerable for pulmonary excessive blood stress in cystic fibrosis are probable to be complex and multifactorial. Commonly, pulmonary high blood stress most customarily growth due to alveolar hypoxia, which induces vasoconstriction in the pulmonary vascular network. Ongoing hypoxemia in the end contributes to vascular damage, inflammatory response accompanied with the aid of way of reactive oxygen species production, and improved workload on the proper element of the coronary heart. In individuals with cystic fibrosis, susceptibility to hypoxemia is mixed with every chronic and acute systemic infection, which might also moreover further boost up pulmonary vascular pathology (T. Spencer *et al.*, 2022).

Musculoskeletal manifestation of cystic fibrosis

as much as 94% of people with cystic fibrosis report experiencing decrease again pain ,which generally has more than one contributing elements. Common causes include weakened muscles, rib fractures, spinal curvature inflammation, burse, and vertebral fracture. Vertebral fracture is particularly prevalent in this population, with an occurrence rate of around 14% interestingly, bone mineral density does not consistently predict the likelihood of vertebral fractures. These fractures can lead to vertebral wedging, which may advance to structure kyphosis if the wedging exceeds 15%. Since vertebral wedging is typically mild, only about 8% of children develop structure kyphosis, while the prevalent almost doubles among adults. This ride is likely due to age related increases in muscle weakness and decreased bone density, including osteopenia and osteoporosis (Mark.2022).

Individual with cystic fibrosis demonstrated reduced respiratory muscles strength compared to healthy control subjects. Several factors are known to impair the ability to generate respiratory muscles force, including structural skeletal abnormalities such as hyper kyphosis, scoliosis, and barrel- shaped chest. Moreover, elevated cytokine concentrations, vitamin D insufficiency corticosteroid Therapy, and generally low physical activity levels can all negatively influence muscle tissue and strength in cystic fibrosis (Niklas, *et al.*, 2024).

The first detailed characterization of age associated musculoskeletal alternation in children with cystic fibrosis. The current research highlighted deficits in epiphyseal bone mass developing during growth in these children, primarily resulting from reductions in trabecular bone material density rather than limitations in bone cross sectional area expansion. For the first time age related modification in bone microarchitecture were documented in cystic fibrosis, showing declines in trabecular number and thickness compared to stable value observed in healthy control children. Additionally, a slower rate of distal tibial cortical shell thickening was noted in children with cystic fibrosis, while cortical bone mineral density and porosity remained similar across age in both groups (Alex, *et al.*, 2023).

Neurological and cognitive aspects of cystic fibrosis:

Individual with cystic fibrosis exhibit chronic systemic inflammation, which may influence brain structure and cognitive ability. Rising level of pro-inflammatory molecules in the circulation can alter the central nervous systems inflammatory status through both direct and indirect mechanism. Evidence indicates that inflammatory mediators, particularly elevated interleukin-6 and C- reactive protein, regulate central inflammatory pathway that can adversely affect cognitive performance. IL-6 receptors are highly concentrated in the hippocampus and prefrontal cortex, and reduced grey matter volume in these regions has been linked to diminish memory and executive functions in healthy adults (Helen K., *et al.*, 2022).

The majority of individuals with cystinosis demonstrate difficulties with visuospatial processing, memory and visuomotor coordination. These challenges are observable even in young children with cystinosis, suggestions an early influence on neural development. Treatment initiated early with cystic- depleting agents does not appear to fully prevalent these deficits, indicating they the underlying cause may involve a very early developmental impact on the brain, potentially linked directly to mutations in cystinosin gene (D. A. 2023).

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

We propose two possible mechanisms through which CFTR dysfunctional may contribute to gradual cognitive impairment. The first mechanism involves a direct influence of CFTR on neural activity. In this study, we evaluated the electrophysiological characteristics of hippocampal neurons. Although long-term potentiation was substantially reduced in cystic fibrosis mice, it remains uncertain whether this effect results directly from CFTR deficiency or indirectly via other processes. CFTR acts as a cAMP-activated ion channels, directly controlling chloride and bicarbonate transport while indirectly affecting intracellular calcium balance. The lack of CFTR could potentially modif6the testing membrane potential and subsequent neuronal depolarization (Danica F., *et al.*, 2025).

Role of microbiome in cystic fibrosis:

Considering the pronounced alternations in the intestinal environment resulting from CFTR dysfunction, it is unsurprising that the gut microbiome in individuals with cystic fibrosis diverges from that of healthy individuals from early life. A prominent feature of the cystic fibrosis gut microbiome is diminished species diversity. Additionally, pediatric studies have indicated that the gut microbiome in children with cystic fibrosis develops and matures at a considerably slower rate than in healthy children (, J. M *et al.*, 2022).

Mycobacteria and fungi have been less extensively investigated than bacteria in bronchiectasis. This can be attributed to limitations in detection methodologies as well as their predisposition for affecting immunocompromised population, resulting in lower research exposure. Basic, meta-evaluation have confirmed regular styles of mycobacteria presence throughout numerous ranges of the disease. However, severe organisms were detected at better frequency inside the undetermined organization. (Yuanyuan, *et al.*, 2025).

Conclusion:

Lifestyles expectancy for individuals with cystic fibrosis has elevated notably, broadly speaking because of the provision of CFTR modulators and the care brought at specialized cystic fibrosis facilities. Though, for the subgroup of sufferers who're ineligible for CFTR modulators therapy, there remains a urgent want for innovation treatment alternatives. Beginning remedy at an early stages is particularly crucial, as it can prevent many disease headaches, emphasized the importance of prompt and accurate diagnosis. Together, the 2020s are anticipated to mark a transformative period for people with cystic fibrosis, with powerful remedies currently available and numerous additional treatment at the horizon. Aggressive treatment strategies are strongly advocated; however, preventive approach to avoid new pulmonary exacerbation are even more essential. In this regard, the early administration of inhaled antibiotics, including newer agents such as levofloxacin, delivered according to a CAIT regimen, may have a crucial role in minimizing exacerbation incidence in patients with cystic fibrosis. Nevertheless, these preliminary observations require through clinical validation before being considered dependable therapeutic to elucidate how the mucus environment influences the susceptibility of pseudomonas aeruginosa biofilms to inhaled antibiotics and to advance the characterization of the respiratory microbiome, thereby optimizing the therapeutic of cystic fibrosis infections with nebulized antibiotic therapy.

REFERENCES

Anwar, S., Peng, J.-L., Zahid, K. R., Zhou, Y.-M., Ali, Q., & Qiu, C.-R. (2024). Cystic fibrosis: Understanding cystic fibrosis transmembrane regulator mutation classification and modulator therapies. *Advances in Respiratory Medicine,* 92(4), 263–277. https://doi.org/10.3390/arm92040026

Bierlaagh, M. C., Muilwijk, D., Beekman, J. M., & van der Ent, C. K. (2021). A new era for people with cystic fibrosis. *European journal of pediatrics*, 180(9), 2731-2739.

Brennan, M. L., & Schrijver, I. (2016). Cystic fibrosis: a review of associated phenotypes, use of molecular diagnostic approaches, genetic characteristics, progress, and dilemmas. *The Journal of Molecular Diagnostics*, 18(1), 3-14.

Burgel, P. R., Burnet, E., Regard, L., & Martin, C. (2024). The changing epidemiology of cystic fibrosis: The implications for adult care. *CHEST*, 163(1), 89–99. https://doi.org/10.1016/j.chest.2022.07.004

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Burgel, P. R., Burnet, E., Regard, L., & Martin, C. (2025). The changing epidemiology of cystic fibrosis: The implications for adult care. *CHEST*, 163(1), 89–99. https://doi.org/10.1016/j.chest.2022.07.004

Burgel, P.-R., Burnet, E., Regard, L., & Martin, C. (2023). The changing epidemiology of cystic fibrosis: *The implications for adult care*. CHEST, 163(1), 89–99. https://doi.org/10.1016/j.chest.2022.07.004

Button, B., Cai, L. H., Ehre, C., Kesimer, M., Hill, D. B., Sheehan, J. K., ... & Rubinstein, M. (2012). A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia. Science, 337(6097), 937-941.

Chadwick, H. K., Abbott, J., Hurley, M. A., Dye, L., Lawton, C. L., Mansfield, M. W., & Peckham, D. (2022). Cystic fibrosis-related diabetes (CFRD) and cognitive function in adults with cystic fibrosis. *Journal of Cystic Fibrosis*, 21(3), 519-528.

Chen, Q., Shen, Y., & Zheng, J. (2021). A review of cystic fibrosis: Basic and clinical aspects. *Animal models and experimental medicine*, 4(3), 220–232. https://doi.org/10.1002/ame2.12180

Chmiel, J. F., & Davis, P. B. (2003). State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection?. Respiratory Research, 4, 8.

Culhane, S., George, C., Pearo, B., & Spoede, E. (2016). Malnutrition in cystic fibrosis: a review. Nutrition in Clinical Practice, 31(4), 474-479.

De Boeck, K., Vermeulen, F., & Dupont, L. (2015). *The diagnosis of cystic fibrosis. La Presse Médicale*, 46(6 Pt 2), e97–e108. https://doi.org/10.1016/j.lpm.2017.04.010

De Boeck, K., Vermeulen, F., & Dupont, L. (2017). The diagnosis of cystic fibrosis. *La Presse Médicale*, 46(6 Pt 2), e97–e108. https://doi.org/10.1016/j.lpm.2017.04.010

Donos, M. A., Ţarcă, E., Cojocaru, E., Ţarcă, V., Butnariu, L. I., Bernic, V., ... & Trandafir, L. M. (2025). Evolution and Prognostic Variables of Cystic Fibrosis in Children and Young Adults: A Narrative Review. *Diagnostics*, 15(15), 1940.

Elborn, J. S. (2016). Cystic fibrosis. The Lancet, 388(10059), 2519-2531.

Elizur, A., Cannon, C. L., & Ferkol, T. W. (2008). Airway inflammation in cystic fibrosis. Chest, 133(2), 489-495.

Fanen, P., Wohlhuter-Haddad, A., & Hinzpeter, A. (2014). Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies. *The International Journal of Biochemistry & Cell Biology*, 52, 94–104. https://doi.org/10.1016/j.biocel.2014.02.023

Farrell, P. M., White, T. B., Ren, C. L., Hempstead, S. E., Accurso, F., Derichs, N., Howenstine, M., McColley, S. A., Rock, M., Rosenfeld, M., Sermet-Gaudelus, I., Southern, K. W., Marshall, B. C., & Sosnay, P. R. (2017). Diagnosis of cystic fibrosis: Consensus guidelines from the Cystic Fibrosis Foundation. *The Journal of Pediatrics*, 181S, S4–S15.e1. https://doi.org/10.1016/j.jpeds.2016.09.064

Grubb, B. R., & Boucher, R. C. (1999). Pathophysiology of gene-targeted mouse models for cystic fibrosis. *Physiological reviews*, 79(1), S193-S214.

Guo, J., Garratt, A., Hill, A., et al. (2022). Worldwide rates of diagnosis and effective treatment for cystic fibrosis. *Journal of Cystic Fibrosis*, 21(3), 456–462. https://doi.org/10.1016/j.jcf.2022.01.009

Ireland, A., Riddell, A., Colombo, A., Ross-Russell, R., Prentice, A., & Ward, K. A. (2023). Development of musculoskeletal deficits in children with cystic fibrosis in later childhood. *Bone*, 170, 116657.

Lambrechts, Mark. "Musculoskeletal Abnormalities Caused by Cystic Fibrosis." Advances in Skeletal Muscle Health and Disease. *IntechOpen*, 2022.

Liberia, Slawomir, et al. "Ocular changes in cystic fibrosis: a review." *International Journal of Molecular Sciences* 25.12 (2024): 6692.

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Lukasiak, A., & Zajac, M. (2021). The distribution and role of the CFTR protein in the intracellular compartments. *Membranes*, 11(11), 804. https://doi.org/10.3390/membranes11110804

Morales, M. M., Capella, M. A. M., & Lopes, A. G. (1999). Structure and function of the cystic fibrosis transmembrane conductance regulator. *Brazilian Journal of Medical and Biological Research*, 32(10), 1021–1028. https://doi.org/10.1590/S0100-879X1999001000001

Moran, A., Brunzell, C., Cohen, R. C., Katz, M., Marshall, B. C., Onady, G., ... & CFRD Guidelines Committee. (2010). Clinical care guidelines for cystic fibrosis-related diabetes. Diabetes Care, 33(12), 2697-2708.

Ong, T., & Ramsey, B. W. (2023). Cystic fibrosis: a review. *Jama*, 329(21), 1859-1871.

Ooi, C. Y., & Durie, P. R. (2016). Cystic fibrosis from the gastroenterologist's perspective. Nature Reviews Gastroenterology & Hepatology, 13(3), 175-185.

Patton-Parfyonov, D. F., Wang, X., Barker, S., Corey, D. A., Vázquez-Rosa, E., Abeyesundere, N., ... & Kelley, T. J. (2021). Cystic Fibrosis-related neurodegenerative disease associated with tauopathy and cognitive decline in aged CF mice. *Journal of Cystic Fibrosis*.

Patton-Parfyonov, D. F., Wang, X., Barker, S., Corey, D. A., Vázquez-Rosa, E., Abeyesundere, N., ... & Kelley, T. J. (2025). Cystic Fibrosis-related neurodegenerative disease associated with tauopathy and cognitive decline in aged CF mice. *Journal of Cystic Fibrosis*.

Poore, T. Spencer, Jennifer L. Taylor-Cousar, and Edith T. Zemanick. "Cardiovascular complications in cystic fibrosis: a review of the literature." *Journal of Cystic Fibrosis* 21.1 (2022): 18-25.

Ratjen, F., & Döring, G. (2003). Cystic fibrosis. The Lancet, 361(9358), 681-689.

Rosenfeld, M., Sontag, M. K., & Ren, C. L. (2016). Cystic Fibrosis Diagnosis and Newborn Screening. Pediatric clinics of North America, 63(4), 599–615. https://doi.org/10.1016/j.pcl.2016.04.004

Roy, R., Das, S., Paul, S., & Jajodia, D. (2025). Cystic fibrosis. *EMJ*, 10(4), 93–105. https://doi.org/10.33590/emj/LFGS7282

Salehzadeh, F., Khoei, F. B., Amani, F., & Mardi, A. (2025). Patients with RIFTD syndrome cystic fibrosis-like disorder: a report of two sibling cases. *Gastroenterology and Hepatology from Bed to Bench*, 18(3), 361.

Scaparrotta, A., Di Pillo, S., & Attanasi, M. (2023). Growth and Nutrition in Cystic Fibrosis. Nutrients, 15(3), 479.

Sheppard, D. N., & Welsh, M. J. (1999). Structure and function of the CFTR chloride channel. *Physiological Reviews*, 79(1), S23–S45. https://doi.org/10.1152/physrev.1999.79.1.S23

Sinderholm Sposato, N., Bjerså, K., Gilljam, M., Lannefors, L., & Fagevik Olsén, M. (2024). Musculoskeletal aspects of respiratory function in cystic fibrosis: a cross-sectional comparative study. *European Clinical Respiratory Journal*, 11(1), 2350206.

Struyvenberg, M. R., Martin, C. R., & Freedman, S. D. (2017). Practical guide to exocrine pancreatic insufficiency – Breaking the myths. BMC Medicine, 15(1), 29.

Taccetti, G., Francalanci, M., Pizzamiglio, G., Messore, B., Carnovale, V., Cimino, G., & Cipolli, M. (2021). Cystic fibrosis: recent insights into inhaled antibiotic treatment and future perspectives. *Antibiotics*, 10(3), 338.

Trauner, D. A. (2023). Neuro-cognitive complications of nephropathic cystinosis. *Journal of Rare Diseases*, 2(1), 8.

Tsui, L. C., & Dorfman, R. (2013). The cystic fibrosis gene: a molecular genetic perspective. *Cold Spring Harbor perspectives in medicine*, 3(2), a009472.

Van Dorst, J. M., Tam, R. Y., & Ooi, C. Y. (2022). What do we know about the microbiome in cystic fibrosis? Is there a role for probiotics and prebiotics? *Nutrients*, 14(3), 480.

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Wang, Y., Xiao, J., Yang, X., Liu, Y., Du, J., Bossios, A., ... & Lundborg, C. S. (2025). Pulmonary microbiology and microbiota in adults with non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis. *Respiratory Research*, 26(1), 7

Wdowiak, N., Choinka, M., Konopka, A., Szczepaniak, Z., Adamska, K., & Kaczmarek, A. (2024). Cystic Fibrosis: A Review of Current Knowledge, Treatment Methods and Diagnostics. *Quality in Sport*, 23, 55065-55065.

Zielenski, J. (2000). Genotype and phenotype in cystic fibrosis. *Respiration*, 67(2), 117-133.